ライフサイエンスコーパス: occlusive disease

1 s intent on the future management of carotid occlusive disease.

2 Two patients had reversible hepatic veno-occlusive disease.

3 from many causes such as diabetes and venous occlusive disease.

4 infarction in patients with vertebral artery occlusive disease.

5 cardial infarction, stroke, and large-vessel occlusive disease.

6 as therapy for Budd-Chiari syndrome and veno-occlusive disease.

7 ave been identified in patients with retinal occlusive disease.

8 mical assessment of lower extremity arterial occlusive disease.

9 order of testing or the severity of arterial occlusive disease.

10 ess the severity of lower extremity arterial occlusive disease.

11 medical evaluation of patients with retinal occlusive disease.

12 in the sickle mouse precipitates acute vaso-occlusive disease.

13 reatment of atherosclerotic carotid arterial occlusive disease.

14 nal aortic aneurysms and 125 were aortoiliac occlusive disease.

15 100-day mortality was the diagnosis of veno-occlusive disease.

16 istic that predicted the development of veno-occlusive disease.

17 iagnosis of chronic lower-extremity arterial occlusive disease.

18 towards a reduction of its susceptibility to occlusive disease.

19 within the intimal plaque in atherosclerotic occlusive disease.

20 ft patency was 99% for aneurysms and 95% for occlusive disease.

21 imal crossing, location, and stenotic versus occlusive disease.

22 patients with symptomatic atherosclerotic VB occlusive disease.

23 m that protects against ischemia in arterial occlusive disease.

24 17 patients (3%) had hepatic veno-occlusive disease.

25 rucial for the development of pulmonary veno-occlusive disease.

26 y less than 3 days to attenuate rebound vaso-occlusive disease.

27 dent Ca(2+) signaling that promotes vascular occlusive disease.

28 saminase and bilirubin without signs of veno-occlusive disease.

29 nction, and a high frequency of hepatic veno-occlusive disease.

30 ped severe hepatotoxicity suggestive of veno-occlusive disease.

31 ge differences in tissue injury in models of occlusive disease.

32 rminants of the severity of tissue injury in occlusive disease.

33 ion in the human kidney affected by vascular occlusive disease.

34 marily the presence and severity of vascular occlusive disease.

35 isk stratification of patients with arterial occlusive disease.

36 tion for lower extremity peripheral arterial occlusive disease.

37 range, 54-80 years) with peripheral arterial occlusive disease.

38 edema due to diabetic retinopathy or venous occlusive disease.

39 ies of patients suspected of having arterial occlusive disease.

40 lenge in clinical treatment of acute thrombo-occlusive diseases.

41 th both asymptomatic and symptomatic carotid occlusive diseases.

42 pathogenesis of atherosclerosis and thrombo-occlusive diseases.

43 atic functions that could attenuate vascular occlusive diseases.

44 ent is common in older patients with carotid occlusive diseases.

45 by participating in the pathogenesis of vaso-occlusive diseases.

46 in linking vascular inflammation and thrombo-occlusive diseases.

47 creased proliferation of SMCs contributed to occlusive diseases.

48 apeutic target for the treatment of vascular occlusive diseases.

49 ny infection, organ failure, or hepatic veno-occlusive disease (1-year cumulative incidence, 71% vs 8

50 ed and symptomatic aortic aneurysms, 399 for occlusive disease, 18 for infected aortic grafts, and 20

51 obal ischemia (10%), and asymptomatic severe occlusive disease (35%).

52 bdominal aortic aneurysm [AAA]: 47 patients; occlusive disease: 86 patients; both: 12 patients).

53 ,500, respectively), whereas infection, veno-occlusive disease, acute graft-versus-host disease, and

54 24-3.33]; P = .002), and peripheral arterial occlusive disease (adjusted HR, 2.15 [95% CI, 1.26-3.66]

55 Atherosclerotic arterial occlusive disease affecting the lower extremities is als

56 capillary hemangiomatosis and pulmonary veno-occlusive disease, an autosomal recessively inherited di

57 ay contribute to the development of arterial occlusive disease and associated clinical events.

58 passes in high-risk patients with aortoiliac occlusive disease and critical ischemia.

59 renal function is at true risk from vascular occlusive disease and determining who will benefit from

60 Rates of veno-occlusive disease and interstitial pneumonitis were high

61 22 patients (mean age, 69 years) with aortic occlusive disease and MAOD and compared the results with

62 treated with dasatinib, peripheral arterial occlusive disease and other arterial disorders in patien

63 risk of death were patients with aortoiliac occlusive disease and patients undergoing bilateral simu

64 d well initially, the patient developed veno-occlusive disease and required repeat transplantation at

65 ed deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectable at

66 ment of extracranial carotid atherosclerotic occlusive disease and the basis of these recommendations

67 ent of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin levels.

68 ents suspected of having peripheral arterial occlusive disease, and diagnostic performance was simila

69 gic feature of luminal narrowing in vascular occlusive diseases, and nothing is yet known regarding t

70 ; (2) posttransplant fever; (3) hepatic veno-occlusive disease; and (4) use of posttransplant growth

71 e 5A and 6A alleles in AAA (n = 405), aortic occlusive disease (AOD) (n = 123) and controls (n = 405)

72 ntly demonstrated in AAA and atherosclerotic occlusive disease (AOD) tissues (six of six), but in onl

73 proteolytic activity in normal aorta, aorto-occlusive disease (AOD), and AAA by use of a novel in si

74 aneurysm (AAA) but more often causes aortic occlusive disease (AOD).

75 Arterial occlusive diseases are major causes of morbidity and mor

76 (presenting as the syndrome of hepatic veno-occlusive disease) are all associated with significant d

77 cause of, respectively, having or not having occlusive disease at the circle of Willis.

78 , organ failure, infections, or hepatic veno-occlusive disease between groups.

79 ipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significant sy

80 he contemporary treatment of coronary athero-occlusive disease by percutaneous transluminal coronary

81 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancytopeni

82 istal territory location, and basilar artery occlusive disease carried the poorest prognosis.

83 (NCF) in patients with severe carotid artery occlusive disease, depending on baseline brain perfusion

84 ypertension and differentiate pulmonary veno-occlusive disease from pulmonary arterial hypertension.

85 s a common mechanism leading to hepatic veno-occlusive disease (HVOD).

86 hy, which mirrors features of human NF1 vaso-occlusive disease, identifies a potential therapeutic ta

87 o worsening pre-existing peripheral arterial occlusive disease in a patient who had received only ima

88 eter-based interventions for lower extremity occlusive disease in an OR/angiography suite.

89 her heterozygosity of Nf1 would lead to vaso-occlusive disease in genetically engineered mice in vivo

90 lso a trend toward an increased risk of veno-occlusive disease in patients with high ferritin.

91 ous limitation in the long-term treatment of occlusive disease in the coronary and peripheral circula

92 is an effective therapy for atherosclerotic occlusive disease in the coronary and peripheral circula

93 stemming from flow reversal,attributable to occlusive disease in the subclavian artery proximal to t

94 dal obstruction syndrome (also known as veno-occlusive disease) in patients during study treatment or

95 ant pathological process in several vascular occlusive diseases, including atherosclerosis and resten

96 tion in native vessels included age, chronic occlusive disease intervention, rotational atherectomy u

97 nial internal carotid artery atherosclerotic occlusive disease is a common ischemic stroke mechanism.

98 Atherosclerotic vertebrobasilar (VB) occlusive disease is a significant etiology of posterior

99 Pulmonary veno-occlusive disease is caused by excessive cell proliferat

100 Severity of tissue injury in occlusive disease is dependent on the extent (number and

101 Chronic lower-extremity occlusive disease is most often manifested by mild sympt

102 and D lesions in superficial femoral artery occlusive disease; ISRCTN48164244).

103 result from an intrinsic cerebral arteriolar occlusive disease, little is known about how these proce

104 changes associated with mesenteric arterial occlusive disease (MAOD) are unknown.

105 199.5 +/- 14.9 SMCs/HPF) and atherosclerotic occlusive disease (n = 6; 176.4 +/- 13.9 SMCs/HPF), but

106 Veno-occlusive disease occurred twice with cyclophosphamide.

107 No additional cases of veno-occlusive disease occurred.

108 l, 0.14-0.96, P = 0.04), peripheral vascular occlusive disease (odds ratio, 0.25; 95% confidence inte

109 ling was associated with peripheral vascular occlusive disease (odds ratio, 0.4; 95% confidence inter

110 atation of proximal internal carotid artery, occlusive disease of terminal internal carotid artery, a

111 Symptomatic atherosclerotic occlusive disease of the innominate artery is a threaten

112 nal aortic aneurysm (33 percent) or arterial occlusive disease of the legs (67 percent).

113 Severe veno-occlusive disease of the liver occurred in 9 (21%) of th

114 nt acute graft-versus-host disease, and veno-occlusive disease of the liver.

115 Additionally, 95 patients developed veno-occlusive disease of the liver.

116 Atherosclerotic vascular occlusive disease of the renal arteries does progress, b

117 reversing the loss of kidney function beyond occlusive disease of the renal arteries poses a major cl

118 initiation of pulmonary vasodilators in veno-occlusive disease often leads to increased mortality.

119 ne administration led to severe hepatic veno-occlusive disease on day 6.

120 tion-related mortality; acute toxicity (veno-occlusive disease or acute graft versus-host disease [Gv

121 ), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6).

122 mpared with normal aorta and atherosclerotic occlusive disease (P < 0.01), and immunoreactive p53 was

123 w L-Ficolin was associated with hepatic veno-occlusive disease (P = .0053, AUC = 0.80).

124 efore the procedure (P<0.01), and peripheral occlusive disease (P=0.04).

125 Peripheral arterial occlusive disease (PAOD) accounts for significant morbid

126 tent claudication due to peripheral arterial occlusive disease (PAOD) is a common cause of pain and d

127 and their heterogeneity in peripheral artery occlusive disease (PAOD) still is limited.

128 Vascular occlusive disease poses a threat to kidney viability, bu

129 Lower extremity peripheral arterial occlusive disease poses a unique challenge to traditiona

130 e hemodynamic impairment associated with the occlusive disease process does not fully account for the

131 ic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis re

132 or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis we

133 with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

134 ne (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

135 Peripheral vascular occlusive disease (PVOD) is a common manifestation of at

136 Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hyp

137 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonar

138 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pulmonar

139 ution of lower extremity peripheral vascular occlusive disease (PVOD).

140 lerotic risk factors and peripheral vascular occlusive disease (PVOD).

141 12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17).

142 randomized patients with peripheral arterial occlusive disease referred for 64-section multidetector

143 ar abnormalities such as arterial and venous occlusive disease, retinal arteriolar macroaneurysm form

144 related macular degeneration, retinal venous occlusive disease, retinopathy of prematurity, and optic

145 of lumen enlargement (growth/remodeling) in occlusive disease, show remarkably wide variation among

146 ccessfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (MOF) i

147 Treosulfan causes less veno-occlusive disease than busulfan and does not require pha

148 novel approach to the treatment of vascular occlusive disease that uses the administration of growth

149 evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-versus-

150 with more severe symptoms of lower-extremity occlusive disease typically have more extensive disease

151 RG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation were s

152 culation in patients with chronic aortoiliac occlusive disease undergoing subclavian transcatheter ao

153 melphalan group had Bearman grades 1-3 veno-occlusive disease versus 21 (9%) of 239 in the carboplat

154 Rates of veno-occlusive disease (VOD) and thrombotic microangiopathy (

155 ction syndrome (SOS), previously called veno-occlusive disease (VOD) can be a difficult problem after

156 We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and retrosp

157 Hepatic veno-occlusive disease (VOD) is a common complication of high

158 Hepatic veno-occlusive disease (VOD) is one of the most serious compl

159 Hepatic veno-occlusive disease (VOD) is the most common of the regime

160 Veno-occlusive disease (VOD) is the most common regimen-relat

161 Hepatic veno-occlusive disease (VOD) is the most serious regimen-rela

162 Veno-occlusive disease (VOD) is the third leading cause of mo

163 ne patient treated at 9 mg/m2 developed veno-occlusive disease (VOD) of the liver and defined the dos

164 The incidence of hepatic veno-occlusive disease (VOD) was 5% for IV-BU and 1% with TBI

165 Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruct

166 ide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement in da

167 2) per day after recognition of hepatic veno-occlusive disease (VOD).

168 dose limiting toxicity (DLT), including veno-occlusive disease (VOD).

169 The incidence of veno-occlusive disease was 40% (13 of 32 patients) in placebo

170 Arterial occlusive disease was detected by reader 1 in 52, 27, an

171 Arterial occlusive disease was detected by reader 2 in 48, 25, an

172 e, which are frequently elevated in arterial occlusive disease, we hypothesized that folic acid forti

173 d December 1997, 52 patients with aortoiliac occlusive disease were treated with endovascular grafts.

174 s undergoing carotid intervention for severe occlusive diseases were prospectively recruited.

175 the 12 patients with mild to severe (but not occlusive) disease were misclassified by one category.

176 essive primary immunodeficiency disease veno-occlusive disease with immunodeficiency syndrome (VODI),